NOT KNOWN DETAILS ABOUT SULFOXAFLOR

All enrolled patients who gained at the least just one dose of zosuquidar or placebo in the course of induction were monitored for the incidence of adverse gatherings (439 individuals, 219 on zosuquidar and 210 on placebo). The most typical adverse situations were connected with the period of prolonged and substantial myelosuppression as is expecte